10.00
+0.17(+1.73%)
Currency In USD
| Previous Close | 9.83 |
| Open | 9.99 |
| Day High | 10.18 |
| Day Low | 9.32 |
| 52-Week High | 25 |
| 52-Week Low | 3.2 |
| Volume | 70,185 |
| Average Volume | 62,233 |
| Market Cap | 194M |
| PE | -3.98 |
| EPS | -2.51 |
| Moving Average 50 Days | 8.94 |
| Moving Average 200 Days | 7.79 |
| Change | 0.17 |
If you invested $1000 in NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) since IPO date, it would be worth $1,038.42 as of January 11, 2026 at a share price of $10. Whereas If you bought $1000 worth of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) shares 6 months ago, it would be worth $2,178.65 as of January 11, 2026 at a share price of $10.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
Newsfile
Yesterday at 12:32 AM GMT
Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies Holdings, Inc. is a
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
GlobeNewswire Inc.
Dec 01, 2025 2:00 PM GMT
CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newl
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
GlobeNewswire Inc.
Nov 14, 2025 9:01 PM GMT
CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today